Skip to main content

IPHA

Stock
Health Care
Biotechnology

Performance overview

IPHA Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Company info

SectorHealth Care
IndustryBiotechnology
Employees239
Market cap$233.6M

Fundamentals

Enterprise value$138.3M
Revenue$23.7M
Revenue per employee
Profit margin-245.87%
Debt to equity350.86

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.72
Dividend per share
Revenue per share$0.25
Avg trading volume (30 day)$21K
Avg trading volume (10 day)$21K
Put-call ratio

Macro factor sensitivity

Growth+1.8
Credit+4.1
Liquidity-1.5
Inflation-1.7
Commodities+1.9
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio4.04
Price to sales8.34
P/E Ratio4.04
Enterprise Value to Revenue5.84
Price to book17.33

Upcoming events

Next earnings daySeptember 15, 2021
Next dividend day
Ex. dividend day

News

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy

Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (April 10, 2024)
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of monalizumab, cetuximab, and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer.

Benzinga (December 9, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free